Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MKAIK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2025019776A2ADC 52-2
|
|||||
| Synonyms |
WO2025019776A2ADC 52-2
Click to Show/Hide
|
|||||
| Organization |
EXELIXIS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
A52
|
Antibody Info | ||||
| Antigen Name |
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
WO2025019776A2, ADC 22-2, Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nuckeophilic lysines
|
|||||
| Combination Type |
Vb-82a
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | ≈2200000 | hr*ng/mL |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -24°C until end of the study.
Click to Show/Hide
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | ≈2200000 | hr*ng/mL |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -24°C until end of the study.
Click to Show/Hide
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | ≈2200000 | hr*ng/mL |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -24°C until end of the study.
Click to Show/Hide
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | ≈2200000 | hr*ng/mL |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -24°C until end of the study.
Click to Show/Hide
|
[1] |
| Clearance (CL) | ≈2.3 | mL/hr/kg |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -25°C until end of the study.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | ≈80 | hr |
Male JVC/FVC cannulated Sprague-Dawley rats (5 per group)were dosed intravenously with a single dose of 5mg/kg of the tested ADC on Day 1 after 16 hours of fasting.100uL K2EDTA plasma was collected at 30 min,4h,24h (on Day 2),168h (on Day 8),240h (on Day 11),336h (on Day 15),and 504h (on Day 22)post-dose,saved in bullet tubes and stored at -25°C until end of the study.
Click to Show/Hide
|
[1] |
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.01 nM | High hIL13Ra2 expression (hIL13Ra2 +++) | ||
| Method Description |
The cytotoxic activity of ADC 52-2 was determined against cancer cell lines A375.FITC and anti-Hen egg-white lysozyme isotype control antibody (HEWL)conjugated to the same linker payloads.
|
||||
| In Vitro Model | Amelanotic melanoma | A375 cells | CVCL_0132 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.02-0.03 nM | Positive hIL13Ra2 expression (hIL13Ra2+++/++) | ||
| Method Description |
The cytotoxic activity of ADC 52-2 was determined against cancer cell lines H1792.FITC and anti-Hen egg-white lysozyme isotype control antibody (HEWL)conjugated to the same linker payloads.
|
||||
| In Vitro Model | Lung adenocarcinoma | H1792 cells | CVCL_1495 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.04-0.08 nM | Positive hIL13Ra2 expression (hIL13Ra2+++/++) | ||
| Method Description |
The cytotoxic activity of ADC 52-2 was determined against cancer cell lines H2228.FITC and anti-Hen egg-white lysozyme isotype control antibody (HEWL)conjugated to the same linker payloads.
|
||||
| In Vitro Model | Lung adenocarcinoma | H2228 cells | CVCL_1543 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3-63 nM | Positive hIL13Ra2 expression (hIL13Ra2+++/++) | ||
| Method Description |
The cytotoxic activity of ADC 52-2 was determined against cancer cell lines SK-MES-1.FITC and anti-Hen egg-white lysozyme isotype control antibody (HEWL)conjugated to the same linker payloads.
|
||||
| In Vitro Model | Lung squamous cell carcinoma | SK-MES-1 cells | CVCL_0630 | ||
